Her2-low/ HRR proficient early triple negative breast cancer is characterized by good prognosis

被引：0
|
作者：
Pellegrino, B. [1 ]
Tornali, C. [2 ]
Lazzarin, A. [3 ]
Cotelli, B. [2 ]
Ingallinella, A. [2 ]
Campanini, N. [4 ]
Tommasi, C. [5 ]
Coriano, M. [6 ]
Serra, O. [7 ]
Michiara, M. [8 ]
Boggiani, D. [9 ]
Schirone, A. [10 ]
Casarini, C. [11 ]
Cretella, E. [12 ]
Zoppoli, G. [13 ,14 ]
Lambertini, M. [15 ]
Botosso, M. [16 ]
Cortesi, L. [17 ]
Silini, E. M. [18 ]
Musolino, A. [19 ]
机构：
[1] Osped Maggiore Parma, Oncol Dept, Parma, Italy
[2] Univ Parma, Oncol, Parma, Italy
[3] Univ Parma, Med Oncol Dept, Parma, Italy
[4] Univ Parma, Fac Med & Chirurg, Pathol, Parma, Italy
[5] Univ Parma, Fac Med & Chirurg, Med Oncol & Breast Unit, Parma, Italy
[6] Azienda Osped Univ Parma, Oncol, Parma, Italy
[7] Univ Parma, Fac Med & Chirurg, Oncol, Parma, Italy
[8] Osped Maggiore Parma, Oncol, Parma, Italy
[9] Univ Hosp Parma, Oncol, Parma, Italy
[10] Arcispedale SantAnna AOU Ferrara, Med, Ferrara, Italy
[11] Nuovo Osped Sassuolo, Oncol, Sassuolo, Italy
[12] Osped Cent Bolzano ASDAA SABES, Oncol Dept, Bolzano, Italy
[13] Univ Genoa, Dept Internal Med, Genoa, GE, Italy
[14] Osped Policlin San Martino IRCCS, DiMI, Genoa, GE, Italy
[15] IRCCS AOU San Martino, IST Ist Nazl Ric Canc, Oncol, Genoa, Italy
[16] IOV Ist Oncol Veneto IRCCS, Oncol, Padua, Italy
[17] Azienda Osped Univ Policlin Modena, Haematol & Oncol Dept, Modena, Italy
[18] Univ Parma, Pathol, Parma, Italy
[19] Univ Parma, Fac Med & Chirurg, Dept Med, Parma, Italy
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.212
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
269P
引用
收藏
页码：S328 / S329
页数：2
相关论文
共 50 条
  • [1] Study of HER2-low expression in triple-negative breast cancer
    Trung, T. Tran
    Ngoc, A. Duong Thi
    Van, T. Nguyen
    Van, T. Ta
    BREAST, 2025, 80
  • [2] Dynamics of HER2-low expression in triple-negative breast cancer
    Garrido-Castro, Ana C.
    Ngo, Lan D.
    Richardson, Edward T.
    Frangieh, Allison
    Mohammed-Abreu, Ayesha
    Hughes, Melissa E.
    Zanudo, Jorge Gomez Tejada
    Navarro, John
    Tarantino, Paolo
    Mittendorf, Elizabeth A.
    Tolaney, Sara
    King, Tari
    Winer, Eric
    Lin, Nancy U.
    Wagle, Nikhil
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Efficacy and prognosis of HER2-Low and HER2-Zero in triple-negative breast cancer after neoadjuvant chemotherapy
    Shi, Zhendong
    Liu, Yingxue
    Fang, Xuan
    Liu, Xu
    Meng, Jie
    Zhang, Jin
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [4] Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple-Negative Breast Cancer
    Yam, Clinton
    Li, Ziyi
    Korkut, Anil
    Ma, Wencai
    Kong, Elisabeth
    Hill, Holly A.
    Abbas, Hussein
    Abouharb, Sausan
    Adrada, Beatriz
    Arun, Banu K.
    Barcenas, Carlos H.
    Bisen, Ajit
    Booser, Daniel
    Buzdar, Aman
    Candelaria, Rosalind
    Chen, Junjie
    Clayborn, Alyson
    Damodaran, Senthil
    Ding, Qingqing
    Garber, Haven
    Hortobagyi, Gabriel N.
    Hunt, Kelly K.
    Ibrahim, Nuhad K.
    Iheme, Adaeze
    Karuturi, Meghan S.
    Koenig, Kimberly
    Layman, Rachel M.
    Lee, Jangsoon
    Litton, Jennifer K.
    Mitchell, Melissa
    Moscol, Giancarlo
    Mouabbi, Jason
    Murthy, Rashmi K.
    Oke, Oluchi
    Pohlmann, Paula
    Ramirez, David
    Ravenberg, Elizabeth
    Saleem, Sadia
    Teshome, Mediget
    Valero, Vicente
    White, Jason
    Williams, Madison
    Woodward, Wendy
    Yajima, Chasity
    Ueno, Naoto T.
    Chen, Ken
    Rauch, Gaiane
    Huo, Lei
    Tripathy, Debu
    CANCER RESEARCH, 2023, 83 (05)
  • [5] HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
    Agostinetto, Elisa
    Rediti, Mattia
    Fimereli, Danai
    Debien, Veronique
    Piccart, Martine
    Aftimos, Philippe
    Sotiriou, Christos
    de Azambuja, Evandro
    CANCERS, 2021, 13 (11)
  • [6] HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Baez-Navarro, Ximena
    van den Ende, Nadine S.
    Nguyen, Anh H.
    Sinke, Renata
    Westenend, Pieter
    van Brakel, Johannes Bastiaan
    Stobbe, Claudia
    Westerga, Johan
    van Deurzen, Carolien H. M.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [7] Clinical characteristics of HER2-low stage I triple-negative breast cancer
    Sanomachi, Tomomi
    Shumiyoshi, Hitomi Okuma
    Kitadai, Rui
    Kawachi, Asuka
    Yazaki, Shu
    Tokura, Momoko
    Arakaki, Motoko
    Saito, Ayumi
    Kita, Shosuke
    Yamamoto, Kasumi
    Maejima, Aiko
    Kojima, Yuki
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Shimoi, Tatsunori
    Noguchi, Emi
    Fujiwara, Yasuhiro
    Suto, Akihiko
    Yonemori, Kan
    ANNALS OF ONCOLOGY, 2023, 34 : S1401 - S1401
  • [8] HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
    Ximena Baez-Navarro
    Nadine S. van den Ende
    Anh H. Nguyen
    Renata Sinke
    Pieter Westenend
    Johannes Bastiaan van Brakel
    Claudia Stobbe
    Johan Westerga
    Carolien H. M. van Deurzen
    Breast Cancer Research, 26
  • [9] The Prognostic Impact of HER2-Low and Menopausal Status in Triple-Negative Breast Cancer
    Park, Woong Ki
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeong Eon
    Yu, Jonghan
    Lee, Se Kyung
    Ryu, Jai Min
    Chae, Byung Joo
    CANCERS, 2024, 16 (14)
  • [10] HER2-low and tumor infiltrating lymphocytes in triple negative breast cancer: are they mutually connected?
    Navarro, X. Baez
    van den Ender, N. S.
    Nguyen, A.
    Sinke, R.
    Westenend, P.
    van Brakel, J. B.
    Stobbe, C.
    Westerga, J.
    van Deurzen, C. H. M.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 104 - 104
12345